The trajectory of Viagra, formerly marketed by copyright, presents a intricate case study for investors considering the pharmaceutical sector. Despite its groundbreaking success and creation of countless in revenue , the intellectual property expiration has opened the floodgates for generic medications, substantially reducing profit opportunities.